Stay updated on Sabatolimab in HMA for Higher Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page.

Latest updates to the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedFooter updates include adding an HHS Vulnerability Disclosure link and updating the Revision from v3.3.1 to v3.3.2; these changes do not modify trial data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check21 days agoChange DetectedAdded a new revision entry 'Revision: v3.3.1' to the history and removed the 'HHS Vulnerability Disclosure' item; the previous 'Revision: v3.2.0' entry remains in the history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check29 days agoChange DetectedThe notice about government funding and NIH operating status in the page footer/banner was removed. This appears to be a cosmetic update with no impact on the study record or its data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check43 days agoChange DetectedA new version entry was added to the Record History for NCT04878432, showing an updated Study Status. This reflects a recent change in the trial's status recorded by ClinicalTrials.gov.SummaryDifference0.1%

- Check57 days agoChange DetectedUpdates date-related references: adds 2025-10-16 and a '23 2025-10-08 Study Status References' entry, and removes 2025-07-31.SummaryDifference1%

- Check71 days agoChange DetectedSignificant: new government funding and operating-status notice plus a version upgrade to v3.2.0. Removed: old version tag v3.1.0.SummaryDifference11%

Stay in the know with updates to Sabatolimab in HMA for Higher Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sabatolimab in HMA for Higher Risk MDS Clinical Trial page.